Advertisement
EDIT vs LCTX
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Lineage Cell Therapeutics (LCTX) Stock Comparison
Key Takeaways
- EDIT is a clinical-stage genome-editing company advancing its lead candidate, EDIT-401, toward first-in-human trials, while LCTX is a clinical-stage cell-therapy company with a diversified, largely partnered pipeline.
- In recent weeks, EDIT has shown stronger relative momentum and received regulatory clearance to begin a Phase 1/2 clinical study, whereas LCTX has faced more consistent selling pressure.
- EDIT relies heavily on a single preclinical-to-early-clinical catalyst, while LCTX spreads risk across multiple programs and strategic partnerships.
- Tickeron AI Verdict: Based on observable trend consistency, catalysts, and relative positioning, the AI framework currently favors EDIT over LCTX.
- For deeper coverage, explore EDIT Major News and EDIT Today's Price Move, along with LCTX Major News and LCTX Today's Price Move.
- To see how automated strategies are navigating this market, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies operating in adjacent but distinct corners of regenerative and genetic medicine. EDIT (Editas Medicine, Inc.) develops CRISPR-based gene editing, while LCTX (Lineage Cell Therapeutics, Inc.) develops "off-the-shelf" cell replacement therapies. Both are pre-revenue or minimally revenue-generating businesses whose valuations hinge on pipeline milestones rather than current earnings. Investors focused on speculative biotech, catalyst-driven price swings, and relative momentum may find this comparison relevant for understanding how two high-risk, high-reward names stack up in the current market environment.
EDIT Overview and Recent Performance
EDIT is a clinical-stage genome-editing company built on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology. After discontinuing its reni-cel sickle cell program and reducing its workforce, the company refocused on in vivo (inside-the-body) editing, with EDIT-401 as its lead candidate. EDIT-401 is a one-time gene-editing therapy targeting the LDLR gene, designed to lower LDL (low-density lipoprotein, or "bad") cholesterol in patients with heterozygous familial hypercholesterolemia.
Recent market activity has reflected renewed optimism around this pipeline pivot. The company reported a narrower-than-expected quarterly loss, and its cash position was described as sufficient to fund operations into the second half of 2028. In recent weeks, EDIT received clearance to begin its Phase 1/2 Strive clinical trial of EDIT-401 in Australia, and several analysts have upgraded the stock, citing the program's progress. These catalysts have contributed to stronger year-to-date relative performance versus its biotech peers, though the shares remain volatile and well below historical highs.
LCTX Overview and Recent Performance
LCTX is a clinical-stage cell-therapy company developing allogeneic (donor-derived, "off-the-shelf") cell replacement treatments. Its pipeline includes OpRegen, a retinal cell therapy for geographic atrophy in age-related macular degeneration (AMD) partnered with Genentech/Roche; OPC1 for spinal cord injury; and earlier-stage programs targeting hearing loss, corneal disease, and type 1 diabetes.
In contrast to EDIT, LCTX has experienced more persistent downward price pressure in recent months, despite maintaining a strongly bullish analyst consensus and a price target implying substantial upside from current levels. Recent developments include the issuance of a patent covering its AlloSCOPE manufacturing platform and an update on its ReSonance hearing-loss program. The company's revenue remains modest and primarily reflects collaboration income, while its runway and pipeline breadth provide diversification that a single-asset competitor does not offer.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that monitor and trade thousands of different tickers across equities, ETFs, and other instruments. Because not every bot suits every market condition, Tickeron curates the strongest performers into a dedicated Trending AI Robots section. These bots differ in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, ranging from short-term momentum approaches to longer-horizon trend strategies. The curated list is designed to highlight the bots most aligned with current market conditions, helping traders evaluate automated options without manually sifting through the full catalog. To explore the strategies currently leading the rankings, visit Trending AI Robots.
Head-to-Head Comparison
The two companies differ sharply in business model and risk profile. EDIT concentrates its strategy on a single lead asset, EDIT-401, creating binary, catalyst-driven outcomes tied to clinical milestones and regulatory steps. LCTX diversifies across multiple programs and monetizes some assets through large partners such as Roche, reducing dependence on any one trial but adding complexity and collaboration-related revenue variability.
On momentum, EDIT has shown comparatively stronger trend consistency in recent weeks, supported by a tangible near-term catalyst in its clinical trial clearance and analyst upgrades. LCTX, by contrast, has trended lower despite favorable ratings, suggesting the market is currently placing greater weight on execution and nearer-term catalysts than on long-term upside targets. Both names carry elevated volatility, are unprofitable, and depend on continued capital to fund research, making them sensitive to sentiment shifts in the broader biotechnology sector.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, recent catalysts, relative positioning, and market sentiment, Tickeron's AI framework currently leans toward EDIT over LCTX. The combination of a fresh clinical-trial clearance, improving analyst sentiment, and comparatively firmer recent price momentum gives EDIT a more constructive short-to-intermediate technical and fundamental setup. This assessment is probabilistic rather than definitive; LCTX's diversified pipeline and strong consensus targets could shift the balance if new data or partnership milestones materialize. The verdict reflects a current, data-driven snapshot rather than a fixed recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and LCTX is a Hold.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for LCTX turns positive, indicating new upward trend
LCTX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 118 similar instances where the indicator turned positive. In 102 of the 118 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
LCTX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
LCTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | LCTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 71 | 61 | |
P/E GROWTH RATING 1..100 | 30 | 34 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LCTX's Valuation (26) in the null industry is in the same range as EDIT (53) in the Biotechnology industry. This means that LCTX’s stock grew similarly to EDIT’s over the last 12 months.
LCTX's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that LCTX’s stock grew similarly to EDIT’s over the last 12 months.
LCTX's SMR Rating (98) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that LCTX’s stock grew similarly to EDIT’s over the last 12 months.
LCTX's Price Growth Rating (61) in the null industry is in the same range as EDIT (71) in the Biotechnology industry. This means that LCTX’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (30) in the Biotechnology industry is in the same range as LCTX (34) in the null industry. This means that EDIT’s stock grew similarly to LCTX’s over the last 12 months.
| EDIT | LCTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 90% | 3 days ago 76% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 81% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 76% |
| Declines ODDS (%) | 1 day ago 90% | 13 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while LCTX’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- LCTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while LCTX’s TA Score has 6 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 6 bearish.
- LCTX’s TA Score: 6 bullish, 3 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -12.50% price change this week, while LCTX (@Biotechnology) price change was +2.97% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
LCTX is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -4.99% | ||
| BEAM - EDIT | 67% Closely correlated | +2.62% | ||
| CRSP - EDIT | 63% Loosely correlated | +1.33% | ||
| SLDB - EDIT | 62% Loosely correlated | +6.00% | ||
| PRME - EDIT | 61% Loosely correlated | +10.26% | ||
| VYGR - EDIT | 61% Loosely correlated | -3.56% | ||
More | ||||
LCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | +6.73% | ||
| EDIT - LCTX | 44% Loosely correlated | -4.99% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.10% | ||
| IMNM - LCTX | 41% Loosely correlated | +2.25% | ||
| FHTX - LCTX | 41% Loosely correlated | +10.00% | ||
| VIR - LCTX | 40% Loosely correlated | -0.15% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| YNOT | 29.41 | 0.95 | +3.35% |
| Horizon Digital Frontier ETF (YNOT) | |||
| JGRO | 90.12 | 1.73 | +1.96% |
| JPMorgan Active Growth ETF (JGRO) | |||
| GRNI | 19.83 | 0.34 | +1.74% |
| Fundstrat Granny Shots Us Large Cap & Income ETF | |||
| XLBI | 23.53 | 0.06 | +0.24% |
| State Street Materials Select Sector SPDR Premium Income ETF (XLBI) | |||
| BHK | 8.45 | -0.04 | -0.47% |
| Blackrock Core BD TR | |||